Efficacy and safety of Olmesartan medoxomil in elderly patients with mild to moderate hypertension

Overview

Phase: Not Applicable
Intervention: Not specified
Conditions: Male or female outpatients, aged 65-89 years, with mild to moderate essential hypertension (sDBP>=90mmHg and sSBP>=140mmHg)
Sponsor: MENARINI INTERNATIONAL OPERATIONS LUXEMBOURG S.A.
Enrollment: 390
Status: Active, not recruiting
Last Updated: 13 years ago

No summary available.

Registry

who.int

Start Date

March 22, 2005

End Date

TBD

Last Updated

13 years ago

Study Type

Interventional clinical trial of medicinal product

Sex

All

Sponsor

•Patients of both sexes responding to the following criteria will be enrolled:
•–age \>65 and \<89 years;
•–new diagnosis of Grade 1 or 2 essential arterial hypertension (systolic arterial pressure when seated 140\-179 mmHg and diastolic arterial pressure when seated 90\-109 mmHg);
•essential arterial hypertension Grade 1 or 2 not controlled with current treatment or with intolerance to current treatment;
•–absence of contraindications with use of Olmesartan medoxomil and Ramipril;
•–letter of informative notes for patient and signature of informed consent;
•–patient residence stable and compatible with the study’s needs;
•–willingness to respect the medical controls planned in the protocol.
•Are the trial subjects under 18? no
•Number of subjects for this age range:

•–Grade 3 essential arterial hypertension (systolic arterial pressure when seated ³ 180 mmHg and/or diastolic arterial pressure when seated ³ 110 mmHg);
•–secondary or malign arterial hypertension;
•–unstable angina;
•–Atrial fibrillation;
•–Frequent ventricular ectopic beats or other arrhytmias which could interfere with blood pressure recording ;
•–cardiac arrhythmia requiring administration of anti\-arrhythmic medicines;
•–heart failure requiring medical treatment;
•–myocardial infarction in the previous 6 months;
•–cerebrovascular events in the previous 6 months;
•–haemodynamically significant valvulopathy;